Edition:
United Kingdom

Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

127.55USD
19 Apr 2018
Change (% chg)

$-0.17 (-0.13%)
Prev Close
$127.72
Open
$127.63
Day's High
$128.26
Day's Low
$126.89
Volume
1,672,897
Avg. Vol
2,414,347
52-wk High
$148.32
52-wk Low
$121.12

Chart for

About

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer... (more)

Overall

Beta: 0.80
Market Cap(Mil.): $357,562.41
Shares Outstanding(Mil.): 2,684.00
Dividend: 0.84
Yield (%): 2.52

Financials

  JNJ.N Industry Sector
P/E (TTM): 22.53 30.95 32.74
EPS (TTM): 5.91 -- --
ROI: 13.49 14.84 14.38
ROE: 22.63 16.34 16.07

Kentucky accuses J&J of contributing to opioid epidemic

Kentucky's attorney general on Wednesday sued Johnson & Johnson, accusing the pharmaceutical manufacturer of devising a deceptive marketing scheme that mischaracterized the risk of opioid abuse and addiction.

18 Apr 2018

UPDATE 1-Kentucky accuses J&J of contributing to opioid epidemic

April 18 Kentucky's attorney general on Wednesday sued Johnson & Johnson, accusing the pharmaceutical manufacturer of devising a deceptive marketing scheme that mischaracterized the risk of opioid abuse and addiction.

18 Apr 2018

Kentucky accuses J&J of contributing to opioid epidemic

April 18 Kentucky's attorney general on Wednesday sued Johnson & Johnson, accusing the pharmaceutical manufacturer of devising a deceptive marketing scheme that mischaracterized the risk of opioid abuse and addiction.

18 Apr 2018

Exclusive - Imerys selling 1 billion euro tiles business, buyout funds bidding: sources

LONDON/FRANKFURT France's Imerys is selling its roof tiles business as it streamlines its portfolio, people close to the matter said, expecting the asset to be valued at around 1 billion euros (£0.9 billion), with private equity most likely to clinch the deal.

18 Apr 2018

Exclusive: Imerys selling one billion euro tiles business, buyout funds bidding - sources

LONDON/FRANKFURT France's Imerys is selling its roof tiles business as it streamlines its portfolio, people close to the matter said, expecting the asset to be valued at around 1 billion euros ($1.2 billion), with private equity most likely to clinch the deal.

18 Apr 2018

J&J raises sales forecast but keeps profit outlook unchanged; shares drop

Johnson & Johnson raised its sales forecast for the year on Tuesday but kept its outlook for full-year profit unchanged, disappointing investors and sending its shares down 1.6 percent.

17 Apr 2018

J&J raises sales forecast on strong demand for cancer drugs

Johnson & Johnson reported a better-than-expected first-quarter profit on Tuesday and raised its full-year sales forecast, helped by strong demand for its cancer treatments.

17 Apr 2018

CORRECTED-UPDATE 1-J&J quarterly profit beats on demand for cancer drugs

April 17 Johnson & Johnson reported a better-than-expected first-quarter profit on Tuesday and raised its full-year sales forecast, helped by growing demand for its cancer drugs.

17 Apr 2018

BRIEF-J&J Says Estimates About 70% Of Cumulative Pre-Tax Costs Relating To Global Supply Chain Actions Will Result In Cash Outlays

* J&J SAYS ESTIMATES THAT ABOUT 70% OF CUMULATIVE PRE-TAX COSTS RELATING TO GLOBAL SUPPLY CHAIN ACTIONS WILL RESULT IN CASH OUTLAYS - SEC FILING Source text: (https://bit.ly/2H9L0dv) Further company coverage:

17 Apr 2018

BRIEF-J&J Posts Q1 Adj Non-Gaap EPS $2.06

* Q1 EARNINGS PER SHARE VIEW $2.02 -- THOMSON REUTERS I/B/E/S

17 Apr 2018

Earnings vs. Estimates